Pellet Power

In contrast to classic single-unit dosage forms such as tablets, the dosage of the drug substance in multi-particulate systems is divided on a plurality of subunits – typically consisting of thousands of spherical pellet particles with a diameter of between 100 and 2,000 μm. This means that non-disintegrating, monolithic single-unit forms retain their structure in the digestive tract, whereas the multi-particular preparations consist of numerous sub-units which disperse after administration. Each single sub-unit then acts as an individual modified release entity. As a consequence of this property, the multiple-unit approach offers certain advantages as a modified release dosage form over preparations such as tablets, including: 
  • Reduced variability of gastric emptying 
  • Reduced dependency on the nutrition state 
  • Minimised risk of high local drug concentrations within the gastrointestinal (GI) tract 
  • Reduced risk of sudden dose-dumping 
  • Lower intra- and inter-individual variability 
  • Controlled onset time of drug release 
  • Delivery of the active ingredient to distal sites within the GI tract 
In addition, with multi-particular pharmaceutical drugs, optimised pharmacokinetic behaviour can improve patient compliance. 

Several creative options can be explored that result in intelligent, sophisticated and reliably acting pharmaceutical dosage forms.The question is: do we have feasible technologies that can establish reproducible product and process quality?